Risks and benefits of Helicobacter pylori eradication: Current status

David Amstrong, Alan Barkun, Marcel Behr, Linda Best, Ted Bosworth, Marc Bradette, Ford Bursey, Hugh Chaun, Naoki Chiba, Alan Cockeram, Ken Croitoru, Carlo Fallone, Nigel Flook, Eric Hassall, Paul Hoffman, Jia Qing Huang, Richard Hunt, Nicola Jones, Monika Keelan, Agnes KleinErnst Kuipers, Raymond Lahaie, Des Leddin, Yves Levasseur, Miller MacSween, Serge Mayrand, James McHattie, Peter Rossos, David Schauer, Phil Sherman, Fiona Smail, Lesley J Smith, Wendy Smith, Jean Spenard, Louise St Onge, Alan B R Thomson, Gervais Tougas, Noel William, Niek de Wit, Sander Veldhuyzen van Zanter

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended. This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities. For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease. The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalCanadian Journal of Gastroenterology
Volume16
Issue number1
StatePublished - Mar 27 2002
Externally publishedYes

Fingerprint

Pylorus
Helicobacter pylori
Canada
Guidelines
Helicobacter Infections
Standard of Care
Microbial Drug Resistance
Gastroesophageal Reflux
Infection
Peptic Ulcer
Stomach Neoplasms
Cost-Benefit Analysis
Therapeutics

Keywords

  • Helicobacter pylori
  • Peptic ulcer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Amstrong, D., Barkun, A., Behr, M., Best, L., Bosworth, T., Bradette, M., ... van Zanter, S. V. (2002). Risks and benefits of Helicobacter pylori eradication: Current status. Canadian Journal of Gastroenterology, 16(1), 57-62.

Risks and benefits of Helicobacter pylori eradication : Current status. / Amstrong, David; Barkun, Alan; Behr, Marcel; Best, Linda; Bosworth, Ted; Bradette, Marc; Bursey, Ford; Chaun, Hugh; Chiba, Naoki; Cockeram, Alan; Croitoru, Ken; Fallone, Carlo; Flook, Nigel; Hassall, Eric; Hoffman, Paul; Huang, Jia Qing; Hunt, Richard; Jones, Nicola; Keelan, Monika; Klein, Agnes; Kuipers, Ernst; Lahaie, Raymond; Leddin, Des; Levasseur, Yves; MacSween, Miller; Mayrand, Serge; McHattie, James; Rossos, Peter; Schauer, David; Sherman, Phil; Smail, Fiona; Smith, Lesley J; Smith, Wendy; Spenard, Jean; St Onge, Louise; Thomson, Alan B R; Tougas, Gervais; William, Noel; de Wit, Niek; van Zanter, Sander Veldhuyzen.

In: Canadian Journal of Gastroenterology, Vol. 16, No. 1, 27.03.2002, p. 57-62.

Research output: Contribution to journalArticle

Amstrong, D, Barkun, A, Behr, M, Best, L, Bosworth, T, Bradette, M, Bursey, F, Chaun, H, Chiba, N, Cockeram, A, Croitoru, K, Fallone, C, Flook, N, Hassall, E, Hoffman, P, Huang, JQ, Hunt, R, Jones, N, Keelan, M, Klein, A, Kuipers, E, Lahaie, R, Leddin, D, Levasseur, Y, MacSween, M, Mayrand, S, McHattie, J, Rossos, P, Schauer, D, Sherman, P, Smail, F, Smith, LJ, Smith, W, Spenard, J, St Onge, L, Thomson, ABR, Tougas, G, William, N, de Wit, N & van Zanter, SV 2002, 'Risks and benefits of Helicobacter pylori eradication: Current status', Canadian Journal of Gastroenterology, vol. 16, no. 1, pp. 57-62.
Amstrong D, Barkun A, Behr M, Best L, Bosworth T, Bradette M et al. Risks and benefits of Helicobacter pylori eradication: Current status. Canadian Journal of Gastroenterology. 2002 Mar 27;16(1):57-62.
Amstrong, David ; Barkun, Alan ; Behr, Marcel ; Best, Linda ; Bosworth, Ted ; Bradette, Marc ; Bursey, Ford ; Chaun, Hugh ; Chiba, Naoki ; Cockeram, Alan ; Croitoru, Ken ; Fallone, Carlo ; Flook, Nigel ; Hassall, Eric ; Hoffman, Paul ; Huang, Jia Qing ; Hunt, Richard ; Jones, Nicola ; Keelan, Monika ; Klein, Agnes ; Kuipers, Ernst ; Lahaie, Raymond ; Leddin, Des ; Levasseur, Yves ; MacSween, Miller ; Mayrand, Serge ; McHattie, James ; Rossos, Peter ; Schauer, David ; Sherman, Phil ; Smail, Fiona ; Smith, Lesley J ; Smith, Wendy ; Spenard, Jean ; St Onge, Louise ; Thomson, Alan B R ; Tougas, Gervais ; William, Noel ; de Wit, Niek ; van Zanter, Sander Veldhuyzen. / Risks and benefits of Helicobacter pylori eradication : Current status. In: Canadian Journal of Gastroenterology. 2002 ; Vol. 16, No. 1. pp. 57-62.
@article{e13be3c97fd24814b7adeff46e4da52a,
title = "Risks and benefits of Helicobacter pylori eradication: Current status",
abstract = "In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended. This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities. For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease. The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients.",
keywords = "Helicobacter pylori, Peptic ulcer",
author = "David Amstrong and Alan Barkun and Marcel Behr and Linda Best and Ted Bosworth and Marc Bradette and Ford Bursey and Hugh Chaun and Naoki Chiba and Alan Cockeram and Ken Croitoru and Carlo Fallone and Nigel Flook and Eric Hassall and Paul Hoffman and Huang, {Jia Qing} and Richard Hunt and Nicola Jones and Monika Keelan and Agnes Klein and Ernst Kuipers and Raymond Lahaie and Des Leddin and Yves Levasseur and Miller MacSween and Serge Mayrand and James McHattie and Peter Rossos and David Schauer and Phil Sherman and Fiona Smail and Smith, {Lesley J} and Wendy Smith and Jean Spenard and {St Onge}, Louise and Thomson, {Alan B R} and Gervais Tougas and Noel William and {de Wit}, Niek and {van Zanter}, {Sander Veldhuyzen}",
year = "2002",
month = "3",
day = "27",
language = "English",
volume = "16",
pages = "57--62",
journal = "Canadian Journal of Gastroenterology and Hepatology",
issn = "2291-2789",
publisher = "Pulsus Group Inc.",
number = "1",

}

TY - JOUR

T1 - Risks and benefits of Helicobacter pylori eradication

T2 - Current status

AU - Amstrong, David

AU - Barkun, Alan

AU - Behr, Marcel

AU - Best, Linda

AU - Bosworth, Ted

AU - Bradette, Marc

AU - Bursey, Ford

AU - Chaun, Hugh

AU - Chiba, Naoki

AU - Cockeram, Alan

AU - Croitoru, Ken

AU - Fallone, Carlo

AU - Flook, Nigel

AU - Hassall, Eric

AU - Hoffman, Paul

AU - Huang, Jia Qing

AU - Hunt, Richard

AU - Jones, Nicola

AU - Keelan, Monika

AU - Klein, Agnes

AU - Kuipers, Ernst

AU - Lahaie, Raymond

AU - Leddin, Des

AU - Levasseur, Yves

AU - MacSween, Miller

AU - Mayrand, Serge

AU - McHattie, James

AU - Rossos, Peter

AU - Schauer, David

AU - Sherman, Phil

AU - Smail, Fiona

AU - Smith, Lesley J

AU - Smith, Wendy

AU - Spenard, Jean

AU - St Onge, Louise

AU - Thomson, Alan B R

AU - Tougas, Gervais

AU - William, Noel

AU - de Wit, Niek

AU - van Zanter, Sander Veldhuyzen

PY - 2002/3/27

Y1 - 2002/3/27

N2 - In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended. This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities. For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease. The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients.

AB - In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended. This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities. For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease. The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients.

KW - Helicobacter pylori

KW - Peptic ulcer

UR - http://www.scopus.com/inward/record.url?scp=0036129893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036129893&partnerID=8YFLogxK

M3 - Article

C2 - 11826340

AN - SCOPUS:0036129893

VL - 16

SP - 57

EP - 62

JO - Canadian Journal of Gastroenterology and Hepatology

JF - Canadian Journal of Gastroenterology and Hepatology

SN - 2291-2789

IS - 1

ER -